Fennec Pharmaceuticals INC 10-Q quarterly reports

Fennec Pharmaceuticals Inc. announced robust second quarter 2026 financial results, driven by a 78% year-over-year increase in PEDMARK net product sales and a significant improvement in Adjusted EBITDA.

Fennec Pharmaceuticals announced first quarter 2026 results, with PEDMARK net sales reaching $15.1 million, a 73% increase year-over-year, driven by market penetration and sales force expansion.

Fennec Pharmaceuticals reported its strongest quarter in history with record net product sales of $12.5 million and its first profitable quarter from operations, driven by increased market penetration of PEDMARK.

Fennec Pharmaceuticals reports strong Q2 2025 net product sales growth of 33% for PEDMARK, driven by increased market penetration and AYA population focus, despite a net loss.

Fennec Pharmaceuticals reports an 18% year-over-year increase in total net revenues for the first quarter of 2025, driven by growth in PEDMARK sales and strategic focus.

Fennec Pharmaceuticals reported a net product sales of $7.0 million for Q3 2024, driven by increasing momentum in the Adolescent and Young Adult (AYA) segment and strategic leadership appointments.

Fennec Pharmaceuticals announced positive second quarter results with $7.3 million in net product sales and the appointment of a new CEO, Jeff Hackman.

Fennec Pharmaceuticals achieved a net revenue of $25.4 million in Q1 2024, primarily driven by a $18 million licensing agreement with Norgine, and $7.4 million in PEDMARK product sales.